A5040310185- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Advanced Breast Cancer Therapies
- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Tumors and Oncological Cases
- Chronic Lymphocytic Leukemia Research
- Cancer Diagnosis and Treatment
- Nutrition and Health in Aging
- SARS-CoV-2 and COVID-19 Research
- PI3K/AKT/mTOR signaling in cancer
- Colorectal and Anal Carcinomas
- Health Systems, Economic Evaluations, Quality of Life
- Computational Drug Discovery Methods
- Advances in Oncology and Radiotherapy
- COVID-19 and healthcare impacts
- BRCA gene mutations in cancer
- COVID-19 Clinical Research Studies
- Cancer therapeutics and mechanisms
European Institute of Oncology
2020-2025
University of Milan
2020-2025
Ripamonti
2022-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2023-2024
The University of Texas MD Anderson Cancer Center
2024
Shanghai Chest Hospital
2022
Shanghai Jiao Tong University
2022
Sapienza University of Rome
2018-2019
Azienda Ospedaliera Sant'Andrea
2019
Abstract Antibody-drug conjugates (ADCs) represent a cornerstone in the treatment of many cancers nowadays. ADCs fulfill their function by binding target on tumor cell membrane to deliver cytotoxic payload; addition, those moieties capable crossing cancer membranes can achieve near-by cells that do not express antigen, exerting so-called “bystander” effect. The presence specific antigen expressed has been for long considered crucial and commonly required inclusion patients clinical trials...
Abstract This study compared OncoSolver (OS), a novel clinical decision tool for matching oncologic patients to trials (CTs), with the manual (MM) process at European Institute of Oncology (IEO) Phase I Unit. Twenty volunteer investigators screened suitable CTs 100 advanced cancer patient profiles (PP) comprehensive treatment history, pathological, genomic and characteristics, modeled on publicly available precision oncology cohorts. OS used rule-based (RB) AI modalities match PP...
Introduction No specific standard treatment is currently recommended for HER2-positive advanced breast cancer (BC) patients progressing to dual HER2 blockade and trastuzumab emtansine (TDM-1). However, several novel anti-HER2 agents are emerging rapidly revolutionizing this setting. Among these, the FC-engineered monoclonal antibody margetuximab has recently demonstrated slightly improve progression-free survival (PFS) compared with trastuzumab, when combined chemotherapy pretreated BC.Areas...
Background and Aims: Sarcopenia, the loss of both lean body skeletal muscle mass, may interfere in cancer patients outcome. As investigated, whey proteins could prevent onset sarcopenia. We have conducted a study to evaluate effects protein colorectal patients, undergoing 5-fluorouracil-based chemotherapy. Methods: After written informed consent, were blind randomized 1:1 (ProLYOtin; arm A) versus placebo (arm B). The assessed physically nutritionally before chemotherapy after 3 (T2) 6...
Platinum-based chemotherapy represents the standard first-line treatment for biliary tract cancers (BTC). Deficits in genes involved homologous recombination (HR) and DNA damage response (DDR) may confer higher sensitivity to platinum agents.
Uterine leiomyosarcoma (uLMS) represents one of the most common sarcoma histotypes, demonstrating an overall dismal prognosis. Previous studies reported uLMS to carry recurrent somatic BRCA2 homozygous deletions, related significant clinical benefits from use PARP inhibitors.